Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation

NCT00167310 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

57

Enrollment

OTHER

Sponsor class

Conditions

Schizophrenia
Schizoaffective Disorder
Major Depression
Bipolar Disorder
Coronary Artery Disease

Interventions

DRUG: Eicosapentaenoic acid (omega-3 fatty acid)
DRUG: Placebo

Sponsor

University of Pittsburgh

Collaborators

[object Object]
[object Object]